White Paper

Understanding GLP-1 Agonists: The ‘Weight Loss’ Drugs Taking the World by Storm

GLP-1 agonist drugs are designed to treat type 2 diabetes, but their secondary weight loss effect is driving popularity.

White Paper Summary

What were once drugs intended for type 2 diabetes, GLP-1 agonists have exploded in popularity due to their secondary function to help lose weight. However, while there are currently 10 GLP-1 agonist drugs on the market, only three of these are FDA approved for the treatment of obesity.

“The weight loss benefits of GLP-1 seem to be what’s driving popularity,” said Kelly Riedl, PA-C, CPHRM, Senior Risk Management Consultant, ProAssurance. “However, because of that popularity we’ve seen supply not being able to keep up with demand, leading to drug shortages.”

Shortages further drive off-label prescribing and have led patients to seek alternative sources, through the web or from compounding pharmacies.

Off-label use of drugs, such as those that are compounded, can play an important role for patients. But it’s important to also note that compounded GLP-1 drugs are not
FDA approved, and thus have not undergone the same testing for safety or quality.

Prescribers and patients alike must better understand the environment surrounding GLP-1 drugs so that they can further increase patient safety and decrease potential liability.

To learn more about ProAssurance, please visit their website.

ProAssurance companies provide comprehensive medical professional liability insurance solutions for healthcare risks of all sizes and types. ProAssurance Group is rated “A” (Excellent) by AM Best.

More from Risk & Insurance